GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004205915 | Thyroid | PTC | negative regulation of epidermal growth factor receptor signaling pathway | 20/5968 | 28/18723 | 2.01e-05 | 2.04e-04 | 20 |
GO:190118514 | Thyroid | PTC | negative regulation of ERBB signaling pathway | 22/5968 | 32/18723 | 2.03e-05 | 2.05e-04 | 22 |
GO:0044409113 | Thyroid | PTC | entry into host | 72/5968 | 151/18723 | 3.48e-05 | 3.29e-04 | 72 |
GO:004825918 | Thyroid | PTC | regulation of receptor-mediated endocytosis | 55/5968 | 110/18723 | 5.64e-05 | 4.99e-04 | 55 |
GO:00103329 | Thyroid | PTC | response to gamma radiation | 32/5968 | 56/18723 | 8.16e-05 | 6.94e-04 | 32 |
GO:1990089110 | Thyroid | PTC | response to nerve growth factor | 32/5968 | 56/18723 | 8.16e-05 | 6.94e-04 | 32 |
GO:0061458112 | Thyroid | PTC | reproductive system development | 173/5968 | 427/18723 | 8.70e-05 | 7.23e-04 | 173 |
GO:004826017 | Thyroid | PTC | positive regulation of receptor-mediated endocytosis | 30/5968 | 52/18723 | 1.06e-04 | 8.56e-04 | 30 |
GO:0036294112 | Thyroid | PTC | cellular response to decreased oxygen levels | 74/5968 | 161/18723 | 1.23e-04 | 9.75e-04 | 74 |
GO:190118410 | Thyroid | PTC | regulation of ERBB signaling pathway | 41/5968 | 79/18723 | 1.70e-04 | 1.31e-03 | 41 |
GO:0048608111 | Thyroid | PTC | reproductive structure development | 170/5968 | 424/18723 | 1.86e-04 | 1.41e-03 | 170 |
GO:00610974 | Thyroid | PTC | regulation of protein tyrosine kinase activity | 45/5968 | 90/18723 | 2.57e-04 | 1.84e-03 | 45 |
GO:004205810 | Thyroid | PTC | regulation of epidermal growth factor receptor signaling pathway | 38/5968 | 73/18723 | 2.69e-04 | 1.91e-03 | 38 |
GO:0097305113 | Thyroid | PTC | response to alcohol | 107/5968 | 253/18723 | 2.92e-04 | 2.07e-03 | 107 |
GO:004592614 | Thyroid | PTC | negative regulation of growth | 105/5968 | 249/18723 | 3.76e-04 | 2.54e-03 | 105 |
GO:00610999 | Thyroid | PTC | negative regulation of protein tyrosine kinase activity | 19/5968 | 31/18723 | 7.02e-04 | 4.39e-03 | 19 |
GO:00466776 | Thyroid | PTC | response to antibiotic | 26/5968 | 47/18723 | 7.38e-04 | 4.59e-03 | 26 |
GO:00065138 | Thyroid | PTC | protein monoubiquitination | 34/5968 | 67/18723 | 1.00e-03 | 5.98e-03 | 34 |
GO:00303087 | Thyroid | PTC | negative regulation of cell growth | 80/5968 | 188/18723 | 1.28e-03 | 7.31e-03 | 80 |
GO:00071764 | Thyroid | PTC | regulation of epidermal growth factor-activated receptor activity | 18/5968 | 30/18723 | 1.38e-03 | 7.74e-03 | 18 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414429 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
hsa0412026 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa0510039 | Esophagus | HGIN | Bacterial invasion of epithelial cells | 30/1383 | 77/8465 | 1.49e-06 | 2.31e-05 | 1.84e-05 | 30 |
hsa0520528 | Esophagus | HGIN | Proteoglycans in cancer | 47/1383 | 205/8465 | 8.23e-03 | 4.71e-02 | 3.74e-02 | 47 |
hsa04144113 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
hsa04120111 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa05100114 | Esophagus | HGIN | Bacterial invasion of epithelial cells | 30/1383 | 77/8465 | 1.49e-06 | 2.31e-05 | 1.84e-05 | 30 |
hsa05205112 | Esophagus | HGIN | Proteoglycans in cancer | 47/1383 | 205/8465 | 8.23e-03 | 4.71e-02 | 3.74e-02 | 47 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0522020 | Esophagus | ESCC | Chronic myeloid leukemia | 61/4205 | 76/8465 | 3.20e-08 | 2.68e-07 | 1.37e-07 | 61 |
hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa05100211 | Esophagus | ESCC | Bacterial invasion of epithelial cells | 59/4205 | 77/8465 | 1.05e-06 | 6.76e-06 | 3.46e-06 | 59 |
hsa049109 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa0401218 | Esophagus | ESCC | ErbB signaling pathway | 56/4205 | 85/8465 | 1.78e-03 | 5.24e-03 | 2.68e-03 | 56 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa05220110 | Esophagus | ESCC | Chronic myeloid leukemia | 61/4205 | 76/8465 | 3.20e-08 | 2.68e-07 | 1.37e-07 | 61 |
hsa0520537 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa05100310 | Esophagus | ESCC | Bacterial invasion of epithelial cells | 59/4205 | 77/8465 | 1.05e-06 | 6.76e-06 | 3.46e-06 | 59 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CBL | SNV | Missense_Mutation | rs759585425 | c.1028N>A | p.Arg343Gln | p.R343Q | P22681 | protein_coding | tolerated(0.07) | possibly_damaging(0.68) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CBL | SNV | Missense_Mutation | | c.397N>C | p.Phe133Leu | p.F133L | P22681 | protein_coding | tolerated(0.22) | probably_damaging(1) | TCGA-AN-A0FT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CBL | SNV | Missense_Mutation | | c.293N>C | p.Ile98Thr | p.I98T | P22681 | protein_coding | deleterious(0.02) | benign(0.422) | TCGA-AR-A24S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
CBL | SNV | Missense_Mutation | novel | c.1501N>C | p.Asp501His | p.D501H | P22681 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CBL | SNV | Missense_Mutation | | c.1619N>C | p.Arg540Pro | p.R540P | P22681 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.997) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CBL | deletion | Frame_Shift_Del | novel | c.2287delN | p.Gly763ValfsTer103 | p.G763Vfs*103 | P22681 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CBL | SNV | Missense_Mutation | novel | c.570N>C | p.Trp190Cys | p.W190C | P22681 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A8YR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
CBL | SNV | Missense_Mutation | | c.1366N>A | p.Asp456Asn | p.D456N | P22681 | protein_coding | deleterious(0) | benign(0.439) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CBL | SNV | Missense_Mutation | | c.416N>T | p.Arg139Ile | p.R139I | P22681 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CBL | SNV | Missense_Mutation | | c.617N>A | p.Arg206Gln | p.R206Q | P22681 | protein_coding | tolerated(0.09) | probably_damaging(0.978) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | Fasudil | FASUDIL | 26177294 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | ANTISENSE OLIGONUCLEOTIDES | | 8849724 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | Gemcitabine | GEMCITABINE | 25348515 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | DASATINIB | DASATINIB | 23696637 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | SU11274 | | 28835699 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | N/A | | 26230957,23690417,19901108 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | Quizartinib | QUIZARTINIB | 22990016 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | IL-2 | ALDESLEUKIN | 9461587 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | Erlotinib | ERLOTINIB | 25348515 |
867 | CBL | KINASE, ENZYME, CLINICALLY ACTIONABLE | | FLT3-LIGAND | | 17446348 |